Jump to content

Cleveland BioLabs betting on future of bioscience in Northeast Ohio

Featured Replies

Posted

First toss since 2000: Cleveland BioLabs betting on future of bioscience in Northeast Ohio

Sunday, April 30, 2006

Mary Vanac

Plain Dealer Reporter

A proposed initial public offering by Cleveland BioLabs Inc. is generat ing buzz in Northeast Ohio financing circles and beyond.

 

The offering is the first bioscience IPO proposed in the region since 2000. Two others were filed but withdrawn during that time.

 

If the offering succeeds, Cleveland BioLabs would be the first local bioscience company to go public since 1996.

 

The Cleveland company, which is developing injectable drugs to ward off radiation and chemical poisoning, also would be the first in the current class of bioscience hopefuls to graduate to the stock market.

 

What could the proposed offering mean for Northeast Ohio? For one, it could be a psychological boost.

 

"Is this good news for Cleveland? Sure it is," said Mike Jackson, an investment banker who is managing director of KeyBanc Capital Markets in Cleveland. Jackson leads the health care group there.

 

More at Cleveland.com

  • 2 months later...

Cleveland Clinic spinoff goes public

BioLabs will use money for drug development

Saturday, July 22, 2006

Shaheen Samavati

Plain Dealer Reporter

 

Cleveland BioLabs Inc., a spinoff of the Cleveland Clinic that is working on anti-radiation and cancer drugs, went public Thursday.

 

The company expects to net $8.5 million from its public offering of 1.7 million shares. The money will go toward further developing and commercializing its first two drugs.

 

BioLabs now expects gross proceeds of the sale to be $10.2 million. But in February, the company's filing with the Securities and Exchange Commission had estimated that proceeds could be as much as $13.8 million.

 

http://staging.hileman.biz/clients/ccf/innovations/web/production/press/BiolabsPublic.pdf

Cleveland BioLabs takes leap into choppy waters for IPOs

By BRANDON GLENN

6:00 am, July 24, 2006

 

If recent months are any indication, the stock of Cleveland Clinic spinoff Cleveland BioLabs Inc. could be in for a bumpy ride after going public last week.

 

Many initial public offerings, and biotech IPOs in particular, have struggled as risk-averse investors seem less willing to wait the years that often must pass before young biotech companies can make the significant progress necessary to generate large investor returns.

 

“The market for all IPOs is not good,” said Les Funtleyder, a health care analyst with Miller Tabak & Co. LLC in New York. “More often than not, it hasn’t been good for health care and particularly bad for biotech.”

 

http://crainscleveland.com/article/20060724/SUB/60721038&SearchID=73297452011986

  • 5 months later...

Wednesday, January 10, 2007  - Cleveland.com

 

Cleveland BioLabs finds new treatment possibilities from drug in development

2:51 p.m.

 

EDIT:  Article removed, no link

Can the following thread be merged with this one? 

http://www.urbanohio.com/forum2/index.php?topic=9778.0

 

Cleveland BioLabs seems to be one of the leading biotech firms in Cleveland right now, having already gone through an IPO.  Hopefully, there will continue to be good news to post here.

 

This was even picked up nationally......

 

AP

Cleveland Biolabs Sees Stem Cell Results

Wednesday January 10, 2:08 pm ET 

Cleveland Biolabs Soars As Company Sees Positive Results in Preclinical Stem Cell Study

 

 

CLEVELAND (AP) -- Biopharmaceutical company Cleveland Biolabs Inc. said Wednesday preclinical studies of its Protectans 600 series stem cells showed the administration of its lead compound increased the number of bone marrow cells in mice.

 

More at:

http://biz.yahoo.com/ap/070110/cleveland_biolabs_product.html?.v=1

$#@%^!  Two days after I post "Cleveland BioLabs seems to be one of the leading biotech firms in Cleveland right now, having already gone through an IPO.  Hopefully, there will continue to be good news to post here.", we get this:

BioLabs looking at move to Buffalo

By JEFF STACKLIN

11:39 am, January 12, 2007

 

EDIT:  Article removed, no link

Full article.....

 

Renowned scientist recruited by Roswell

 

--------------------------------------------------------------------------------

Cleveland cancer expert to bring biotech company

 

By JONATHAN D. EPSTEIN

News Business Reporter

1/12/2007 

 

Roswell Park Cancer Institute has recruited a high-level cancer researcher from the Cleveland Clinic who will also bring the publicly traded biotechnology company he founded and nearly three dozen jobs, hospital and company officials said Thursday.

 

More at:

http://www.buffalonews.com/editorial/20070112/1055272.asp

I was just about to post that!  :-D

 

But seriously, what jerks!  :shoot: 

Is this a ploy to squeeze money out of Cleveland or Ohio?

 

What the hell good is it to have companies spin off from the Cleveland Clinic only to land in other cities? If we can't keep the spin-offs here, then that's a major embarassment.

"In the souls of the people the grapes of wrath are filling and growing heavy, growing heavy for the vintage." -- John Steinbeck

Here is an article from Crains. This really stinks. :wtf: I am a pharmacy student, and we have a lot of small pharm. companies come to talk to us, and the frusturating thing is that most of these companies just want to do prelim. research in hopes of being bought out by a larger company. I know Cleveland BioLabs is not being bought out, but I just thought I would bring this issue to light.

 

Cleve BioLabs plans move to Buffalo

Cleveland BioLabs Inc., a publicly traded company that was spun out of the Cleveland Clinic, is planning to move its headquarters to Buffalo later this year.

 

The biotech company will follow its founder, Andrei V. Gudkov, a cancer researcher at the Clinic, to the Roswell Park Cancer Institute in Buffalo, said Cleveland BioLabs CEO Michael Fonstein.

 

Dr. Gudkov’s lab, including 15 to 20 scientists and technicians, will move to the Buffalo Niagara Medical Campus this spring. About 20 to 30 additional employees will move into a building just off campus that will serve as Cleveland BioLabs’ headquarters, said Mike Sexton, general counsel and chief institute operations officer at Roswell Park.

 

http://www.crainscleveland.com/article/20070112/FREE/70112018

i'm sorry, but "cancer institute" just doesn't sound right.

  • 2 months later...

Too bad only 1/2 the company (and not the HQ) is left in Cleveland.  $30 million is a significant amount of financing.  From Crain's:

 

Cleveland BioLabs closes private placement

By SCOTT SUTTELL

1:40 pm, March 19, 2007

 

Cleveland BioLabs Inc. (Nasdaq: CBLI) said it has closed a $30 million private placement that the biotech company plans to use to advance its pipeline of compounds to meet the requirements of a potential government contract.

 

More at:

http://www.crainscleveland.com/apps/pbcs.dll/article?AID=/20070319/FREE/70319005/1007/2020&Profile=1007

 

I will never understand the stock market.  That would seem like good news for the company, but the stock drops?

^Maybe the market was assuming a bigger round of financing. 

  • 2 months later...

Cleveland BioLabs compound could be breakthrough

Posted by Mary Vanac May 21, 2007 13:50PM

Categories: Breaking News

A compound being commercialized by Cleveland BioLabs Inc. helped regenerate bone marrow stem cells in mice that received transplants.

 

Blood from healthy mice treated by the compound, Protectan CBLB612, was transplanted into mice that received lethal doses of radiation, killing their bone marrow stem cells. Without these stem cells, a mouse cannot produce blood cells and dies.

 

More at:

http://blog.cleveland.com/business/2007/05/cleveland_biolabs_compound_cou.html

  • 7 months later...

Ouch!

 

Cleveland BioLabs Loses Contract Bid

Friday January 4, 9:02 am ET 

Cleveland BioLabs Shares Sink in Premarket Trading on Defense Dept. Contract Loss

 

BUFFALO, N.Y. (AP) -- Shares of Cleveland BioLabs Inc. lost half their value Friday in premarket trading after the company lost a Department of Defense contract bid to Osiris Therapeutics Inc.

The stock fell $3.98, or 49.8 percent to $4.02 in premarket trading, setting up a record low opening. Meanwhile, Osiris shares surged $4.43, or 35.2 percent, to $17 in premarket trading.

 

more at:

http://biz.yahoo.com/ap/080104/cleveland_biolabs_contract.html?.v=1

^ That's the company that moved to Buffalo last year right?

Yeah, yet they are still called Cleveland BioLabs.....  They supposedly still have some kind of presence in Cleveland though(research).

Otherwise no sympathy.. 

Create an account or sign in to comment

Recently Browsing 0

  • No registered users viewing this page.